Concerning ALS Awareness Month.
Senate Resolution 26-009 is a commemorative resolution designating May 2026 as ALS Awareness Month in Colorado. The resolution describes amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, as a progressive and fatal neurodegenerative disease, and it highlights the lack of a known cure, the typical short survival time after diagnosis, and the importance of research, clinical trials, and multidisciplinary care for people living with ALS.
The resolution also emphasizes the impact of ALS on military veterans, the need for access to therapies, durable medical equipment, and communication technologies, and the role of organizations such as the ALS Association and ALS United Rocky Mountain in supporting patients and clinics in Colorado. It calls on Coloradans to support ALS research, advocate for increased funding, and stand in solidarity with affected individuals and families. The resolution is directed to several health-care and advocacy leaders and is intended to raise awareness rather than change substantive law.
This resolution does not amend, create, or repeal any Colorado statutes. Its legal effect is limited to an official Senate proclamation recognizing May 2026 as ALS Awareness Month and encouraging public support for ALS research and care. The practical impact is symbolic and advocacy-oriented, with potential to elevate attention to ALS clinics, research funding, veteran health concerns, and patient support services in Colorado.
The sentiment around the resolution is strongly supportive and compassionate. The bill’s sponsors and the Senate as a whole appear to view ALS as a devastating disease deserving public recognition, increased awareness, and greater research investment. The final reading passed with no amendments, indicating broad agreement and little visible opposition.
There is no recorded committee debate, vote split, or amendment activity suggesting substantive contention. Because the resolution is ceremonial and nonbinding, it does not appear to have generated disagreement over policy details. Any underlying issues mentioned in the text—such as funding for research, access to therapies and equipment, or support for veterans and multidisciplinary clinics—are framed as shared priorities rather than disputed points.